TABLE 1.

Analysis of the association between LILRs gene expression and clinical outcomes.

Gene	Overall survival				Relapse‐free survival
	Patients	MST (days)	HR (95% CI)	p #	Patients	MST (days)	HR (95% CI)	p*
LILRA1
Lower	56	473	Reference		46	486	Reference
Higher	56	596	0.60 (0.35–1.03)	0.064	47	716	0.66 (0.31–1.40)	0.281
LILRA2
Lower	56	473	Reference		46	439	Reference
Higher	56	596	0.58 (0.33–1.02)	0.058	47	872	0.35 (0.16–0.76)	0.008
LILRA4
Lower	56	375	Reference		46	593	Reference
Higher	56	614	0.46 (0.27–0.80)	0.006	47	716	0.50 (0.23–1.04)	0.065
LILRA5
Lower	56	485	Reference		48	542	Reference
Higher	56	568	0.82 (0.49–1.38)	0.454	45	831	0.80 (0.39–1.63)	0.537
LILRA6
Lower	56	481	Reference		45	593	Reference
Higher	56	614	0.91 (0.52–1.60)	0.735	48	620	0.75 (0.37–1.50)	0.411
LILRB1
Lower	56	498	Reference		45	486	Reference
Higher	56	592	0.68 (0.40–1.17)	0.164	48	716	0.59 (0.27–1.27)	0.178
LILRB2
Lower	56	485	Reference		46	486	Reference
Higher	56	592	0.85 (0.50–1.45)	0.552	47	831	0.61 (0.30–1.28)	0.193
LILRB3
Lower	56	458	Reference		46	593	Reference
Higher	56	614	0.59 (0.34–1.04)	0.066	47	716	0.60 (0.29–1.23)	0.162
LILRB4
Lower	56	473	Reference		48	486	Reference
Higher	56	603	0.57 (0.33–097)	0.040	45	716	0.46 (0.22–0.96)	0.038
LILRB5
Lower	56	476	Reference		44	593	Reference
Higher	56	596	0.75 (0.43–1.31)	0.318	49	716	0.80 (0.38–1.66)	0.545

Note: Multivariate cox proportional hazards regression model was ^#adjusted by neoplasm histological grade, targeted molecular therapy, radiation therapy, residual resection in overall survival and *adjusted by Neoplasm histological grade, residual resection in relapse‐free survival.

Abbreviations: CI, confidence interval; HR, hazard ratio; LILRs, leukocyte immunoglobulin‐like receptors; MST, median, survival time.